X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ASTRAZENECA PHARMA GSK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 59.5 92.8 64.1% View Chart
P/BV x 11.7 13.2 88.3% View Chart
Dividend Yield % 2.1 0.0 -  

Financials

 GSK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
GSK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8501,285 299.6%   
Low Rs2,966634 467.8%   
Sales per share (Unadj.) Rs332.3189.6 175.3%  
Earnings per share (Unadj.) Rs44.3-0.2 -21,757.1%  
Cash flow per share (Unadj.) Rs47.23.8 1,228.4%  
Dividends per share (Unadj.) Rs50.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs202.768.6 295.4%  
Shares outstanding (eoy) m84.7025.00 338.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.35.1 202.6%   
Avg P/E ratio x76.9-4,712.7 -1.6%  
P/CF ratio (eoy) x72.2249.6 28.9%  
Price / Book Value ratio x16.814.0 120.3%  
Dividend payout %112.90-   
Avg Mkt Cap Rs m288,64323,988 1,203.3%   
No. of employees `0004.61.6 295.8%   
Total wages/salary Rs m4,4341,605 276.3%   
Avg. sales/employee Rs Th6,104.53,040.2 200.8%   
Avg. wages/employee Rs Th961.61,029.2 93.4%   
Avg. net profit/employee Rs Th813.7-3.3 -24,922.8%   
INCOME DATA
Net Sales Rs m28,1484,740 593.9%  
Other income Rs m1,21892 1,322.7%   
Total revenues Rs m29,3664,832 607.8%   
Gross profit Rs m4,774-130 -3,677.8%  
Depreciation Rs m248101 245.1%   
Interest Rs m00-   
Profit before tax Rs m5,744-139 -4,135.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m26139 18.7%   
Tax Rs m2,0185 39,646.4%   
Profit after tax Rs m3,752-5 -73,713.2%  
Gross profit margin %17.0-2.7 -619.3%  
Effective tax rate %35.1-3.7 -958.7%   
Net profit margin %13.3-0.1 -12,412.2%  
BALANCE SHEET DATA
Current assets Rs m21,4622,726 787.2%   
Current liabilities Rs m10,5362,435 432.7%   
Net working cap to sales %38.86.1 631.3%  
Current ratio x2.01.1 181.9%  
Inventory Days Days6874 91.7%  
Debtors Days Days1641 40.3%  
Net fixed assets Rs m4,7171,035 455.6%   
Share capital Rs m84750 1,694.0%   
"Free" reserves Rs m16,308942 1,730.5%   
Net worth Rs m17,1711,716 1,000.7%   
Long term debt Rs m160-   
Total assets Rs m30,6204,156 736.8%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 80.6%   
Return on assets %12.3-0.1 -10,005.1%  
Return on equity %21.9-0.3 -7,366.4%  
Return on capital %33.60-  
Exports to sales %05.7 0.2%   
Imports to sales %15.16.5 232.9%   
Exports (fob) Rs m4270 1.5%   
Imports (cif) Rs m4,237306 1,383.3%   
Fx inflow Rs m519375 138.5%   
Fx outflow Rs m8,320470 1,769.6%   
Net fx Rs m-7,801-96 8,164.0%   
CASH FLOW
From Operations Rs m1,386-8 -17,106.2%  
From Investments Rs m5,010-146 -3,438.3%  
From Financial Activity Rs m-6,383862 -740.4%  
Net Cashflow Rs m12709 1.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 15.7 151.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 12,856 793.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS